NEW YORK, NY / ACCESSWIRE / February 05, 2016 / Park Lane Advisor has initiated coverage on the following equities: Biogen Inc. (NASDAQ: BIIB), Medivation Inc. (NASDAQ: MDVN), Grifols S.A. (NASDAQ: GRFS), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Free note on Biogen can be accessed at http://www.parklaneadvisor.com/ On Thursday, February 04, 2016, the NASDAQ Composite ended at 4,509.56, up 0.12%, the Dow Jones Industrial Average advanced 0.49%, to finish the day at 16,416.58, and the S&P 500 closed at 1,915.45, up 0.15%. The gains were broad based as five out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
Biogen Inc.'s stock advanced 1.05%, to close the day at $273.27. The stock recorded a trading volume of 2.07 million shares, above its three months average volume of 1.85 million shares. The company's shares are trading 4.06% below their 50-day moving average. Additionally, Biogen Inc. traded at a PE ratio of 17.81 and has a Relative Strength Index (RSI) of 48.50. Sign up and read the free notes on BIIB at:
http://www.parklaneadvisor.com/
On Thursday, shares in Medivation Inc. recorded a trading volume of 2.44 million shares, higher than their three months average volume of 1.81 million shares. The stock ended the day 1.42% lower at $30.56. Shares of the company traded at a PE ratio of 19.59. The company is trading below its 50-day and 200-day moving averages by 25.38% and 37.62%, respectively. Furthermore, shares of Medivation Inc. have an RSI of 25.88. The complimentary notes on MDVN can be downloaded in PDF format at:
http://www.parklaneadvisor.com/
Grifols S.A.'s stock finished Thursday's session 0.54% higher at $14.78. A total of 1.60 million shares were traded, which was above its three months average volume of 1.14 million shares. The company's shares are trading below their 50-day and 200-day moving averages by 7.34% and 7.40%, respectively. Grifols S.A.'s stock traded at a PE ratio of 35.19 and has an RSI of 41.34. Register for free on Park Lane Advisor and access the latest research on GRFS at:
http://www.parklaneadvisor.com/
On Thursday, shares in Agios Pharmaceuticals Inc. ended the session 3.10% higher at $37.94. The stock reported a trading volume of 1.74 million shares, above its three months average volume of 0.75 million shares. The company is trading 31.70% below its 50-day moving average and 55.46% below its 200-day moving average. Moreover, shares of Agios Pharmaceuticals Inc. have an RSI of 34.20. The complete research on AGIO is available for free at:
http://www.parklaneadvisor.com/
--
About Park Lane Advisor:
Park Lane Advisor ("PLA") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. PLA has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PLA has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the Sponsor have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the Sponsor (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.
NO WARRANTY
PLA, the Author, the Reviewer and the Sponsor (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PLA nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.ParkLaneAdvisor.com
RESTRICTIONS
PLA is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
E-mail: media (at) ParkLaneAdvisor (dot) com
SOURCE: Park Lane Advisor
